Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? the Losartan Intervention for Endpoint reduction in hypertension study Academic Article Article uri icon

Overview

MeSH Major

  • Cardiovascular Diseases
  • Diabetes Mellitus, Type 2
  • Hypertrophy, Left Ventricular

abstract

  • During follow-up of hypertensive patients with LVH, occurrence of MI but not coronary revascularization as first cardiovascular event significantly increased risk of subsequent cardiovascular death, all-cause death, and stroke. In view of differences in prognostic implications, when the goal is to have a prognostically relevant composite endpoint for trials in hypertensive patients, caution should be used in combining coronary revascularization with MI.

publication date

  • June 2010

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/HJH.0b013e328337a9c8

PubMed ID

  • 20486280

Additional Document Info

start page

  • 1134

end page

  • 40

volume

  • 28

number

  • 6